NASDAQ:IDRA up more than 60% pre-market on positive results!

(Nasdaq:IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands, regarding its investigator-sponsored trial, INTRIM 1, involving tilsotolimod, Ideras synthetic Toll-like receptor 9 agonist. Based on these results, the trial has been stopped early.

XTON, Pa., May 17, 2022 (GLOBE NEWSWIRE) — Idera Pharmaceuticals, Inc. (Idera, we, and our) (Nasdaq:IDRA) today shared positive interim results from Amsterdam UMC, Vrije Universiteit Amsterdam, the Netherlands, regarding its investigator-sponsored trial, INTRIM 1, involving tilsotolimod, Ideras synthetic Toll-like receptor 9 agonist. Based on these results, the trial has been stopped early.

https://www.globenewswire.com/news-release/2022/05/17/2444956/33448/en/Idera-Pharmaceuticals-Shares-Positive-Results-from-Investigator-Sponsored-Trial-in-Melanoma-Patients-at-Amsterdam-UMC.html

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.